ATTACHMENT B
Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-23. (Canceled)

24. (Currently Amended) A method of preparing a glycoalkaloid preparation which comprises at least one glycoalkaloid of the general formula I:



(I)

wherein:

either one of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



Each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, alkyl and R^4O-alkylene; each of R^4 is a radical separately selected from the group consisting of hydrogen and carbohydrate "X" is a radical selected from the group consisting of $–CH_2$-,-O- and –NH-;

wherein the compound includes at least one R^4 group in which R^4 is a carbohydrate

the method including the step of removing free sugars ~~being degradation products of the glycoalkaloid from the~~ from a solid glycoalkaloid preparation.

25. (Previously Presented) The method of claim 24 wherein R^4 is selected from the group consisting of glyceric aldehyde; glycerose; erythrose; threose; ribose; arabinose; xylose; lyxose; altrose; allose; gulose; mannose; glucose; idose; galactose; talose; rhamnose; dihydroxyactone; erythrulose; ribulose; xylulose; psicose; fructose; sorbose; tagatose; and other hexoses ($C_6H_{12}O_6$); heptoses ($C_7H_{14}O_7$); octoses ($C_8H_{16}O_8$); nanoses ($C_9H_{18}O_9$); decoses ($C_{10}H_{20}O_{10}$); deoxysugars with branched chains;

compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted; sugar alcohols; sugar acids; benzimidazoles; the enol salts of the carbohydrates; saccharinic acids; sugar phosphates.

26. (Previously Presented) The method of claim 24 wherein the at least one glycoalkaloid is selected from the group consisting of solasonine, solamargine, and tomatine.

27. (Previously Presented) The method of claim 24 wherein the free sugar is rhamnose, or a disaccharide, trisaccharide, oligosaccharide or polysaccharide having rhamnose as a sugar moiety thereof.

28. (Currently Amended) The method claim 24 wherein the solid glycoalkaloid preparation is also treated to remove any aglycone therefrom.

29. (Currently Amended) The method of claim 24 wherein essentially all the free sugars are removed from the solid glycoalkaloid preparation by washing the extract with an aqueous solvent.

30. (Previously Presented) The method of claim 28 wherein the aglycone is removed from the preparation by washing the preparation with an chlorinated hydrocarbon solvent.

31. (Previously Presented) The method of claim 30 wherein chlorinated hydrocarbon is chloroform.

32. (Previously Presented) The method of claim 24 wherein a time period of at least about 7 days has elapsed between the extraction and removal steps.

33. (Previously Presented) A glycoalkaloid preparation produced according to the method of claim 24.

34. (Previously Presented) A medicinal composition comprising a glycoalkaloid preparation according to claim 33 and a pharmaceutically acceptable carrier, adjuvant, excipient and/or diluent.

35. (Previously Presented) The composition of claim 34, wherein the at least one glycoalkaloid is selected from the group consisting of solasonine, solamargine, and tomatine.

36. (Previously Presented) The composition of claim 34, wherein the at least one glycoalkaloid is BEC.

37. (Previously Presented) The composition of claim 34 in a form suitable for topical administration.

38. (Previously Presented) The composition of claim 34, which includes between at least about 0.001% to about 5% wt of the at least one glycoalkaloid.

39. (Previously Presented) The composition of claim 34, which is in a form suitable for administration by injection.

40. (Previously Presented) The composition of claim 39, which includes a liquid carrier selected from the group consisting of DMSO, acetic acid and lactic acid.

41. (Previously Presented) The composition of claim 34, which includes a stabilizing agent for stabilizing the at least one glycoalkaloid.

42. (Previously Presented) A method for the treatment or control of cancer in a mammal requiring such treatment, the method comprising administering to said mammal an effective amount of the medicinal composition of claim 34.

43. (Currently Amended) A method of preparing a glycoalkaloid preparation which comprises at least one glycoalkaloid of the general formula I:



(I)

wherein:

either one of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds;

A: represents a radical selected from the following radicals of general formulae (II) to (V):



Each of R^1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR^4; each of R^2 is a radical separately selected from the group consisting of hydrogen, amino and OR^4; each of R^3 is a radical separately selected from the group consisting of hydrogen, alkyl and R^4O-alkylene; each of R^4 is a radical separately selected from the group consisting of hydrogen and carbohydrate "X" is a radical selected from the group consisting of $-CH_2-$,-O- and –NH-;

wherein the compound includes at least one R^4 group in which R^4 is a carbohydrate;

the method including extracting the at least one glycoalkaloid from a suitable plant material to form ~~an~~ a solid extract and removing free sugars being degradation products of the glycoalkaloid from the solid extract.

44. (Previously Presented) The method of claim 43, wherein R^4 is selected from the group consisting of glyceric aldehyde; glycerose; erythrose; threose; ribose; arabinose; xylose; lyxose; altrose; allose; gulose; mannose; glucose; idose; galactose; talose; rhamnose; dihydroxyactone; erythrulose; ribulose; xylulose; psicose; fructose; sorbose; tagatose; and other hexoses ($C_6H_{12}O_6$); heptoses ($C_7H_{14}O_7$); octoses ($C_8H_{16}O_8$); nanoses ($C_9H_{18}O_9$); decoses ($C_{10}H_{20}O_{10}$); deoxysugars with branched chains; compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted; sugar alcohols; sugar acids; benzimidazoles; the enol salts of the carbohydrates; saccharinic acids; sugar phosphates.

45. (Previously Presented) The method of claim 43, wherein the at least one glycoalkaloid is selected from the group consisting of solasonine, solamargine, and tomatine.

46. (Previously Presented) The method of claim 43 wherein the plant material is from a plant of the Solanum genus.

47. (Previously Presented) The method of claim 43, wherein the extract is BEC.

48. (Previously Presented) The method of claim 43, wherein the free sugar is rhamnose, or a disaccharide, trisaccharide, oligosaccharide or polysaccharide having rhamnose as a sugar moiety thereof.

49. (Previously Presented) The method of claim 43 wherein the extract is also treated to remove any aglycone therefrom.

50. (Currently Amended) The method of claim 43 wherein essentially all the free sugars are removed from the solid extract by washing the extract with an aqueous solvent.

51. (Currently Amended) The method of claim 49 wherein the aglycone is removed from the solid extract by washing the preparation with a chlorinated hydrocarbon solvent.

52. (Previously Presented) A method of claim 51 wherein chlorinated hydrocarbon is chloroform.

53. (Previously Presented) The method of claim 43 wherein a time period of at least about 7 days has elapsed between the extraction and removal steps.

54. (Previously Presented) A glycoalkaloid preparation produced according to the method of claim 43.

55. (Previously Presented) A medicinal composition comprising a glycoalkaloid preparation according to claim 54 and a pharmaceutically acceptable carrier, adjuvant, excipient and/or diluent.

56. (Previously Presented) The composition of claim 55, wherein the at least one glycoalkaloid is selected from the group consisting of solasonine, solamargine, and tomatine.

57. (Previously Presented) The composition of claim 55, wherein the at least one glycoalkaloid is BEC.

58. (Previously Presented) The composition of claim 55 in a form suitable for topical administration.

59. (Previously Presented) The composition of claim 55, which includes between at least about 0.001% to about 5% wt of the at least one glycoalkaloid.

60. (Previously Presented) The composition of claim 55, which is in a form suitable for administration by injection.

61. (Previously Presented) The composition of claim 60, which includes a liquid carrier selected from the group consisting of DMSO, acetic acid and lactic acid.

62. (Previously Presented) The composition of claim 55, which includes a stabilizing agent for stabilizing the at least one glycoalkaloid.

63. (Previously Presented) A method for the treatment or control of cancer in a mammal requiring such treatment, the method comprising administering to said mammal an effective amount of the medicinal composition of claim 55.

64. (New) The method of claim 24, wherein said step of removing free sugar from a solid glycoalkaloid preparation comprises removing essentially all of the free sugar from the glycoalkaloid preparation.

65. (New) A glycoalkaloid preparation produced by the method of claim 64, said preparation being essentially without free sugar.

66. A medicinal composition comprising a glycoalkaloid preparation according to claim 65 and a pharmaceutically acceptable carrier, adjuvant, excipient and/or diluent.